Inhibikase Therapeutics Target Price

Inhibikase Therapeutics (IKT) currently reports a target price of $6.5. Use the charts on this page to explore Inhibikase Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Inhibikase Therapeutics is $6.5, about 225.0% upside from the current share price of $2.0. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $6.5, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Inhibikase Therapeutics, and consider following IKT for alerts when major investors trade the stock.

Inhibikase Therapeutics is classified in the Healthcare sector. On target price, it currently shows $6.5. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IKT with unrelated industries.